Live MediSum Demo

In a randomized, open‑label phase II trial in 56 older and/or frail patients with stage III unresectable NSCLC ineligible for concurrent chemoradiotherapy, sequential chemo‑immunotherapy was followed by either standard or reduced thoracic radiotherapy. At median 24 months follow‑up, 1‑year progression‑free survival was numerically higher with standard versus reduced RT in the intention‑to‑treat analysis (84.3% vs 70.7%), while grade 3–4 adverse events were more frequent with standard RT (71.4% vs 53.6%); the trial was non‑comparative, small, and not powered for definitive superiority or non‑inferiority. The authors conclude reduced RT may be feasible with numerically similar survival outcomes but highlight the need for larger randomized trials.

This retrospective analysis of EGFR-mutated NSCLC included 43 patients who received neoadjuvant immunochemotherapy followed by surgery and 499 patients who underwent surgery alone, examining associations with tumor PD-L1 TPS. In the neoadjuvant group, baseline PD-L1 ≥1% correlated with better radiologic response and increases in PD-L1 were associated with major pathologic response; in the adjuvant group, PD-L1 ≥50% independently predicted shorter disease-free survival and PD-L1 ≥1% was linked to more frequent TP53 co-mutations and poorer survival in external cohorts.

In samples from patients with high-grade serous ovarian carcinoma, tumors with high genomic instability activated tumor-intrinsic STING signaling and secreted WNT3a/7a, which induced WNT/β-catenin signaling in fibroblasts to epigenetically lock them into a POSTN-expressing myofibroblast-like CAF lineage. These POSTN myCAFs expanded effector regulatory T cells and exhausted CD8 T cells, converting genome-instability–driven immune activation into immunosuppression and limiting PARP inhibitor efficacy, while therapeutic POSTN blockade restored T cell cytotoxicity, depleted effector Tregs, and potentiated PARP inhibition in ovarian and breast cancer models.